Mathieu Bonmort
Overview
Explore the profile of Mathieu Bonmort including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Terme M, Mignot G, Ullrich E, Bonmort M, Minard-Colin V, Jacquet A, et al.
Cancer Res
. 2009 Aug;
69(16):6590-7.
PMID: 19679551
IFN producing killer dendritic cells (IKDC) were originally defined as CD11c(int) B220(+)NK1.1(+) (or CD49b(+)) cells that exert a potent tumoricidal activity in animals lacking B, T, and conventional natural killer...
2.
Bonmort M, Dalod M, Mignot G, Ullrich E, Chaput N, Zitvogel L
Curr Opin Immunol
. 2008 Jun;
20(5):558-65.
PMID: 18554881
Tumors can regress as a result of invading myeloid and lymphoid cells that act in concert. Although the myeloid cells are widely recognized as antigen presenters and lymphoid cells as...
3.
Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al.
J Immunol
. 2008 Jun;
180(12):7887-97.
PMID: 18523252
IFN-producing killer dendritic cells (IKDC) were initially described as B220(+)CD11c(+)CD3(-)NK1.1(+) tumor-infiltrating cells that mediated part of the antitumor effects of the combination therapy with imatinib mesylate and IL-2. In this...
4.
Zitvogel L, Mignot G, Bonmort M, Ullrich E, Chaput N
Med Sci (Paris)
. 2008 May;
24(5):525-8.
PMID: 18466731
No abstract available.
5.
Mignot G, Ullrich E, Bonmort M, Menard C, Apetoh L, Taieb J, et al.
J Immunol
. 2008 May;
180(10):6477-83.
PMID: 18453565
The synergistic antitumor effects of the combination therapy imatinib mesylate (IM) and IL-2 depended upon NK1.1- expressing cells and were associated with the accumulation of CD11c(int)B220(+)NK1.1(+) IFN-producing killer dendritic cells...
6.
Ullrich E, Menard C, Flament C, Terme M, Mignot G, Bonmort M, et al.
Cytokine Growth Factor Rev
. 2007 Dec;
19(1):79-92.
PMID: 18155952
Tumor growth results from a delicate balance between intrinsic dysregulation of oncogenes, tumor suppressor and stability genes counteracted by extrinsic defenses composed of immune cells shaping tumor immunogenicity. Although immune...
7.
Bonmort M, Ullrich E, Mignot G, Jacobs B, Chaput N, Zitvogel L
Biochimie
. 2007 Jun;
89(6-7):872-7.
PMID: 17574720
Interferon-gamma is a key cytokine in tumor immunosurveillance. The recently described interferon-producing killer dendritic cell (IKDC), can be distinguished from other innate effectors by its ability to kill a large...
8.
Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Menard C, et al.
Cancer Res
. 2007 Feb;
67(3):851-3.
PMID: 17283111
A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent...
9.
Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, et al.
Nat Med
. 2006 Jan;
12(2):214-9.
PMID: 16444265
The interferon (IFN)-gamma-induced TRAIL effector mechanism is a vital component of cancer immunosurveillance by natural killer (NK) cells in mice. Here we show that the main source of IFN-gamma is...